- Home
- RNXT vs ARTV Comparison
RNXT vs ARTV Comparison
Compare RNXT & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- ARTV
- Stock Information
- Founded
- RNXT 2012
- ARTV 2019
- Country
- RNXT United States
- ARTV United States
- Employees
- RNXT N/A
- ARTV N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- ARTV
- Sector
- RNXT Health Care
- ARTV
- Exchange
- RNXT Nasdaq
- ARTV NYSE
- Market Cap
- RNXT 44.6M
- ARTV 39.0M
- IPO Year
- RNXT 2021
- ARTV 2024
- Fundamental
- Price
- RNXT $1.32
- ARTV $2.12
- Analyst Decision
- RNXT Strong Buy
- ARTV Strong Buy
- Analyst Count
- RNXT 2
- ARTV 8
- Target Price
- RNXT $7.25
- ARTV $18.14
- AVG Volume (30 Days)
- RNXT 150.2K
- ARTV 370.0K
- Earning Date
- RNXT 08-14-2025
- ARTV 08-28-2025
- Dividend Yield
- RNXT N/A
- ARTV N/A
- EPS Growth
- RNXT N/A
- ARTV N/A
- EPS
- RNXT N/A
- ARTV N/A
- Revenue
- RNXT $240,000.00
- ARTV N/A
- Revenue This Year
- RNXT $3,104.65
- ARTV N/A
- Revenue Next Year
- RNXT $301.89
- ARTV N/A
- P/E Ratio
- RNXT N/A
- ARTV N/A
- Revenue Growth
- RNXT N/A
- ARTV N/A
- 52 Week Low
- RNXT $0.75
- ARTV $1.47
- 52 Week High
- RNXT $1.69
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- RNXT 50.28
- ARTV N/A
- Support Level
- RNXT $1.28
- ARTV N/A
- Resistance Level
- RNXT $1.40
- ARTV N/A
- Average True Range (ATR)
- RNXT 0.07
- ARTV 0.00
- MACD
- RNXT -0.01
- ARTV 0.00
- Stochastic Oscillator
- RNXT 40.74
- ARTV 0.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).